SAVAZ Trademark

Trademark Overview


On Wednesday, November 8, 2017, a trademark application was filed for SAVAZ with the United States Patent and Trademark Office. The USPTO has given the SAVAZ trademark a serial number of 87676277. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 30, 2020. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The SAVAZ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
savaz

General Information


Serial Number87676277
Word MarkSAVAZ
Filing DateWednesday, November 8, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 30, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 4, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, November 17, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Trademark Events


Event DateEvent Description
Monday, November 30, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 30, 2020ABANDONMENT - NO USE STATEMENT FILED
Thursday, April 30, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 28, 2020EXTENSION 3 GRANTED
Tuesday, April 28, 2020EXTENSION 3 FILED
Tuesday, April 28, 2020TEAS EXTENSION RECEIVED
Wednesday, October 23, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 25, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 23, 2019EXTENSION 2 GRANTED
Wednesday, October 23, 2019EXTENSION 2 FILED
Wednesday, October 23, 2019TEAS EXTENSION RECEIVED
Friday, April 26, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 24, 2019EXTENSION 1 GRANTED
Wednesday, April 24, 2019EXTENSION 1 FILED
Wednesday, April 24, 2019TEAS EXTENSION RECEIVED
Tuesday, October 30, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 4, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 4, 2018PUBLISHED FOR OPPOSITION
Wednesday, August 15, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, July 27, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, July 26, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 26, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 26, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 21, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 21, 2018NON-FINAL ACTION E-MAILED
Wednesday, February 21, 2018NON-FINAL ACTION WRITTEN
Wednesday, February 21, 2018ASSIGNED TO EXAMINER
Friday, November 17, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, November 11, 2017NEW APPLICATION ENTERED IN TRAM